Mobile Streams PLC heads north as change of direction bears fruit proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces its unaudited interim results for the six months ended 30 September 2020. · Dr Huw Jones appointed as Chief Executive Officer · Completion of first out-licensing deal with Juvenescence for use of Sulforadex® technology in non-pharmaceutical markets. Up to $10.5m receivable in milestones with royalties on sales · Phase IIb/III trial using SFX-01 for acute respiratory distress syndrome ( ARDS ) including COVID-19 patients sponsored by Dundee University, with grant funding from LifeArc; the STAR trial ( SFX-01 treatment for acute respiratory infections) · Patient recruitment commenced in STAR trial post the period end with data potentially available in Q4 2021.